Modifier genes and their effect on Duchenne muscular dystrophy

Current Opinion in Neurology

Volumn 28, Issue 5, 2015, Pages 528-534

  Vo, Andy H ^a   McNally, Elizabeth M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Latent transforming growth factor binding; Muscular dystrophy; Osteopontin; Transforming growth factor

Indexed keywords

CALCIUM BINDING PROTEIN; CALPHOBINDIN II; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 4; OSTEOPONTIN; PROTEIN ANXA6; TRANSCRIPTOME; UNCLASSIFIED DRUG; LTBP4 PROTEIN, HUMAN; SPP1 PROTEIN, HUMAN;

APOPTOSIS; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURFACE; COHORT ANALYSIS; CONFORMATIONAL TRANSITION; DUCHENNE MUSCULAR DYSTROPHY; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENOME; HUMAN; MODIFIER GENE; NONHUMAN; PROGNOSIS; PROTEIN DEGRADATION; REVIEW; SARCOLEMMA; SINGLE NUCLEOTIDE POLYMORPHISM; SPP1 GENE; ANIMAL; GENETICS;

ANIMALS; ANNEXIN A6; GENES, MODIFIER; HUMANS; LATENT TGF-BETA BINDING PROTEINS; MUSCULAR DYSTROPHY, DUCHENNE; OSTEOPONTIN;

EID: 84941781335     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000240     Document Type: Review

References (50)

1. Emery AE. Population frequencies of inherited neuromuscular diseases: a world survey. Neuromuscul Disord 1991; 1:19-29.
2. Romitti P, Puzhankara S, Mathews K, et al. Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007. MMWR Morb Mortal Wkly Rep 2009; 58:1119-1122.
3. Manzur AY, Kuntzer T, Pike M, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008; CD003725.
4. McNally EM, Passos-Bueno MR, Bonnemann CG, et al. Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation. Am J Hum Genet 1996; 59:1040-1047.
5. Shi M, Zhu J, Wang R, et al. Latent TGF-beta structure and activation. Nature 2011; 474:343-349.
6. Schiller M, Javelaud D, Mauviel A. TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J Dermatol Sci 2004; 35:83-92.
7. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science 2002; 296:1646-1647.
8. Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol 2008; 40:383-408.
9. Hocevar BA, Brown TL, Howe PH. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 1999; 18:1345-1356.
10. Biressi S, Miyabara EH, Gopinath SD, et al. A Wnt-TGFbeta2 axis induces a fibrogenic program in muscle stem cells from dystrophic mice. Sci Transl Med 2014; 6:267ra176.
11. Verrecchia F, Mauviel A. Control of connective tissue gene expression by TGF beta: role of Smad proteins in fibrosis. Curr Rheumatol Rep 2002; 4:143-149.
12. Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther 2015; 23:192-201.
13. Chen YW, Nagaraju K, Bakay M, et al. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 2005; 65:826-834.
14. MacDonald EM, Cohn RD. TGFbeta signaling: its role in fibrosis formation and myopathies. Curr Opin Rheumatol 2012; 24:628-634.
15. Bernasconi P, Torchiana E, Confalonieri P, et al. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 1995; 96:1137-1144.
16. Onofre-Oliveira PC, Santos AL, Martins PM, et al. Differential expression of genes involved in the degeneration and regeneration pathways in mouse models for muscular dystrophies. Neuromolecular Med 2012; 14:74-83.
17. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312:117-121.
18. Burks TN, Andres-Mateos E, Marx R, et al. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med 2011; 3:82ra37.
19. Nelson CA, Hunter RB, Quigley LA, et al. Inhibiting TGF-beta activity improves respiratory function in mdx mice. Am J Pathol 2011; 178:2611-2621.
20. Dadgar S, Wang Z, Johnston H, et al. Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy. J Cell Biol 2014; 207:139-158.
21. Goldstein JA, Bogdanovich S, Beiriger A, et al. Excess SMAD signaling contributes to heart and muscle dysfunction in muscular dystrophy. Hum Mol Genet 2014; 23:6722-6731.
22. Cohen TV, Kollias HD, Liu N, et al. Genetic disruption of Smad7 impairs skeletal muscle growth and regeneration. J Physiol 2015; 593:2479-2497.
23. Accornero F, Kanisicak O, Tjondrokoesoemo A, et al. Myofiber-specific inhibition of TGFbeta signaling protects skeletal muscle from injury and dystrophic disease in mice. Hum Mol Genet 2014; 23:6903-6915.
24. Kemaladewi DU, Pasteuning S, van der Meulen JW, et al. Targeting TGF-beta signaling by antisense oligonucleotide-mediated knockdown of TGF-beta type I receptor. Mol Ther Nucleic Acids 2014; 3:e156.
25. Uaesoontrachoon K, Yoo HJ, Tudor EM, et al. Osteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitro. Int J Biochem Cell Biol 2008; 40:2303-2314.
26. Hullinger TG, Pan Q, Viswanathan HL, et al. TGFbeta and BMP-2 activation of the OPN promoter: roles of smad- and hox-binding elements. Exp Cell Res 2001; 262:69-74.
27. Piva L, Gavassini BF, Bello L, et al. TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle. J Pathol 2012; 228:251-259.
28. Biros E, Clancy P, Norman PE, et al. A genetic polymorphism in transforming growth factor beta receptor-2 is associated with serum osteopontin. Int J Immunogenet 2009; 36:241-244.
29. Vetrone SA, Montecino-Rodriguez E, Kudryashova E, et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest 2009; 119:1583-1594.
30. Pegoraro E, Hoffman EP, Piva L, et al. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 2011; 76:219-226.
31. Giacopelli F, Marciano R, Pistorio A, et al. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 2004; 20: 87-96.
32. Bello L, Kesari A, Gordish-Dressman H, et al. Genetic modifiers of ambulation in the cooperative international Neuromuscular research group Duchenne natural history study. Ann Neurol 2015; 77:684-696.
33. Bello L, Piva L, Barp A, et al. Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology 2012; 79:159-162.
34. van den Bergen JC, Hiller M, Bohringer S, et al. Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants. J Neurol Neurosurg Psychiatry 2014. [Epub ahead of print]. doi: 10.1136/jnnp-2014-308409.
35. Flanigan KM, Ceco E, Lamar KM, et al. LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Ann Neurol 2013; 73: 481-488.
36. Turk R, Sterrenburg E, van der Wees CG, et al. Common pathological mechanisms in mouse models for muscular dystrophies. Faseb j 2006; 20:127-129.
37. Saharinen J, Keski-Oja J. Specific sequence motif of 8-Cys repeats of TGFbeta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol Biol Cell 2000; 11:2691-2704.
38. Su CT, Huang JW, Chiang CK, et al. Latent transforming growth factor binding protein 4 regulates transforming growth factor beta receptor stability. Hum Mol Genet 2015; 14:4024-4036.
39. Todorovic V, Rifkin DB. LTBPs, more than just an escort service. J Cell Biochem 2012; 113:410-418.
40. Heydemann A, Ceco E, Lim JE, et al. Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. J Clin Invest 2009; 119:3703-3712.
41. Ceco E, Bogdanovich S, Gardner B, et al. Targeting latent TGFbeta release in muscular dystrophy. Sci Transl Med 2014; 6:259ra144.
42. Swaggart KA, Heydemann A, Palmer AA, et al. Distinct genetic regions modify specific muscle groups in muscular dystrophy. Physiol Genomics 2011; 43:24-31.
43. Swaggart KA, Demonbreun AR, Vo AH, et al. Annexin A6 modifies muscular dystrophy by mediating sarcolemmal repair. Proc Natl Acad Sci U S A 2014; 111:6004-6009.
44. Camors E, Monceau V, Charlemagne D. Annexins and Ca2+ handling in the heart. Cardiovasc Res 2005; 65:793-802.
45. Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005; 6:449-461.
46. Carmeille R, Degrelle SA, Plawinski L, et al. Annexin-A5 promotes membrane resealing in human trophoblasts. Biochim Biophys Acta 2015; doi:10.1016/ j.bbamcr.2014.12.038. [Epub ahead of print]
47. Lennon NJ, Kho A, Bacskai BJ, et al. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem 2003; 278: 50466-50473.
48. Cagliani R, Magri F, Toscano A, et al. Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies. Hum Mutat 2005; 26:283.
49. Roostalu U, Strahle U. In vivo imaging of molecular interactions at damaged sarcolemma. Dev Cell 2012; 22:515-529.
50. Tas F, Tilgen Yasasever C, Karabulut S, et al. Circulating annexin A2 as a biomarker in gastric cancer patients: correlation with clinical variables. Biomed Pharmacother 2015; 69:237-241.